These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 21896743)

  • 1. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
    Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
    Hu J; Muller KA; Furnari FB; Cavenee WK; VandenBerg SR; Gonias SL
    Oncogene; 2015 Jul; 34(31):4078-88. PubMed ID: 25347738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
    Gilder AS; Jones KA; Hu J; Wang L; Chen CC; Carter BS; Gonias SL
    J Biol Chem; 2015 Jun; 290(24):14798-809. PubMed ID: 25837250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.
    Eastman BM; Jo M; Webb DL; Takimoto S; Gonias SL
    Cell Signal; 2012 Sep; 24(9):1847-55. PubMed ID: 22617030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase receptor primes cells to proliferate in response to epidermal growth factor.
    Jo M; Thomas KS; Takimoto S; Gaultier A; Hsieh EH; Lester RD; Gonias SL
    Oncogene; 2007 Apr; 26(18):2585-94. PubMed ID: 17043637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
    Blomquist MR; Eghlimi R; Beniwal A; Grief D; Nascari DG; Inge L; Sereduk CP; Tuncali S; Roos A; Inforzato H; Sharma R; Pirrotte P; Mehta S; Fortin Ensign SP; Loftus JC; Tran NL
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.
    Raghu H; Gondi CS; Dinh DH; Gujrati M; Rao JS
    Mol Cancer; 2011 Oct; 10():130. PubMed ID: 22004682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator.
    Jo M; Thomas KS; Marozkina N; Amin TJ; Silva CM; Parsons SJ; Gonias SL
    J Biol Chem; 2005 Apr; 280(17):17449-57. PubMed ID: 15728176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
    Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
    Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
    Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
    Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
    Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
    Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
    Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib and erlotinib inhibits growth of c-Met
    Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
    Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
    Estrada-Bernal A; Lawler SE; Nowicki MO; Ray Chaudhury A; Van Brocklyn JR
    J Neurooncol; 2011 May; 102(3):353-66. PubMed ID: 20938717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
    Latha K; Li M; Chumbalkar V; Gururaj A; Hwang Y; Dakeng S; Sawaya R; Aldape K; Cavenee WK; Bogler O; Furnari FB
    Int J Cancer; 2013 Feb; 132(3):509-20. PubMed ID: 22729867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.
    Liu XJ; Wu WT; Wu WH; Yin F; Ma SH; Qin JZ; Liu XX; Liu YN; Zhang XY; Li P; Han S; Liu KY; Zhang JM; He QH; Shen L
    CNS Neurosci Ther; 2013 Jul; 19(7):494-502. PubMed ID: 23575351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.